The next era for mRNA-based therapeutics and vaccines is here, and it’s time to move from an R&D mindset to a focus on long-term success with mRNA and bringing these innovative therapeutics to patients at scale.
Moderna is partnering with Life Edit, a subsidiary of ElevateBio that offers a suite of gene-editing technologies. The deal brings together the capabilities of both companies, which aim to develop in vivo gene-editing therapies.Mod
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Moderna and Merck have been partners in the development of messenger RNA cancer vaccines since 2016. Merck is deepening the alliance by exercising an option that enables it to share equally in further work on a partnered cancer vaccine for melanoma.
Arpeggio Biosciences raised $17 million in a Series A funding round led by Builders VC. The startup is focused on measuring the transcriptome — which refers to the full range of mRNA molecules expressed by an organism — to develop better therapeutics.
Merck aims to bolster its genetic medicines pipeline through a new research alliance with Orna Therapeutics, a startup whose technology forms RNA into a circle shape that brings several advantages for new therapies and vaccines. In addition to starting the partnership, the pharmaceutical giant also invested in Orna’s $221 million Series B financing round.
Kernal Biologics has technology that enables the delivery of messenger RNA therapies to a wider range of destinations in the body. The Series A financing comes as the startup works to advance its lead immuno-oncology program toward its first clinical test.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Alnylam Pharmaceuticals has proprietary lipid nanoparticle technology used in its FDA-approved RNA therapies. The biotech company claims that the messenger RNA Covid-19 vaccines from Moderna and Pfizer infringe on a patent covering this LNP technology.
Scientists developing new RNA drugs need to understand how proteins bind to these molecules. Eclipsebio’s technology provides that analysis and the biotech startup now has a Series A round of funding to scale up its business.
ARCH Venture Partners led the Series C round of financing for Nutcracker Therapeutics, a company developing new RNA drugs. The company’s process for developing and manufacturing RNA therapies borrows from techniques used in the technology sector.
Alltrna, a biotech startup founded by Flagship Pioneering, is developing a new type of medicine based on a form of RNA called transfer RNA, or tRNA. The company’s scientists say that this approach offers the potential to treat a wide range of diseases, both rare and common.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Covid-19 vaccine booster shots are now authorized for organ transplant patients and others who have weakened immune systems. The FDA based its update on the results of two small studies that tested third shots of the mRNA Covid vaccines from Moderna and Pfizer/BioNTech.
Sanofi is acquiring Translate Bio, its messenger RNA R&D partner for the past three years, in a $3.2 billion deal. The pharmaceutical and vaccines giant said the acquisition will speed up development of partnered vaccine programs and spark work on new ones in areas such as cancer, immunology, and rare diseases.
Messenger RNA therapies are coming in many forms and Strand Therapeutics is developing “next generation” treatments that can be programmed with features and functions, similar to how software code is written. Led by CEO Jacob Becraft, the startup has raised $52 million to support its R&D.
Too many cold chain suppliers are still monitoring deliveries and storage compliance with paper-based documentation by individuals scanning thermometers every two hours. Such systems fall short of 21st-Century requirements for biologic medicine.
Moderna's leadership team dodged questions about their assessment of the largely slow and dysfunctional vaccine rollout focusing instead of telling the story of the science behind a decade-old biopharma company whose first commercial product is making history.